Following successful CD8 and NK cell depletion (Fig. 5g, h, l, m), the delayed tumor growth conferred by anti-CTLA-4 and anti-TIGIT therapies was partially lost, suggesting that these responses are mediated by both CTLs and NK cells (Fig. 5f, k and Supplementary Fig. 6h). The gene discussed is CTLA4; the disease is neoplasm.